Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha
详细信息 查看全文
- 作者：Saiko Kurosawa1 ; skurosaw@ncc.go.jp" class="auth_mail" title="E-mail the corresponding author ; Hiroki Yamaguchi2 ; Takuhiro Yamaguchi3 ; Keiko Fukunaga2 ; Shunsuke Yui2 ; Satoshi Wakita2 ; Heiwa Kanamori4 ; Kensuke Usuki5 ; Nobuhiko Uoshima6 ; Masamitsu Yanada7 ; Katsuhiro Shono8 ; Toshimitsu Ueki9 ; Ishikazu Mizuno10 ; Shingo Yano11 ; Jin Takeuchi12 ; Junya Kanda13 ; Hiroshi Okamura14 ; Yoshihiro Inamoto1 ; Koiti Inokuchi2 ; Takahiro Fukuda1
- 关键词：Acute myeloid leukemia ; Hematopoietic cell transplantation ; Decision analysis ; Quality of life
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：22
- 期：6
- 页码：1125-1132
- 全文大小：855 K
文摘
- •
Allogeneic hematopoietic cell transplantation was a favored postremission strategy in patients with FLT3-internal tandem duplication
- •
Chemotherapy was a favored strategy in patients with biallelic CCAAT/enhancer binding protein alpha mutations, and allogeneic hematopoietic cell transplantation was favored in those without biallelic CCAAT/enhancer binding protein alpha mutations
- •
In patients without FLT3-internal tandem duplication, hematopoietic cell transplantation improved life expectancies with or without nucleophosmin; however, robustness of the results was not shown by sensitivity analyses